FRM
ELVN icon

Fox Run Management’s Enliven Therapeutics ELVN Stock Holding History

Fox Run Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Sell
6,709
-8,864
-57% -$376K 0.06% 623
2026
Q1 		$570K Buy
15,573
+3,141
+25% +$87K 0.1% 380
2025
Q4 		$191K Buy
+12,432
New +$248K 0.03% 813

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Fox Run Management's ELVN Position: Q2 2026 in Review

Fox Run Management reduced its Enliven Therapeutics (ELVN) stake by 57% in Q2 2026, selling an estimated $376K and leaving 6,709 shares worth $340K. The position accounts for 0.06% of the portfolio, ranked #623.

Fox Run Management first reported a position in ELVN in Q4 2025 and has held it in 3 quarters since. The position peaked at $570K in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Fox Run Management held 6,709 shares of Enliven Therapeutics worth $340K as of Q2 2026.
  • Fox Run Management sold 8,864 Enliven Therapeutics shares in Q2 2026, an estimated $376K.
  • Enliven Therapeutics made up 0.06% of Fox Run Management's portfolio in Q2 2026, its #623 holding.
  • Fox Run Management first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Fox Run Management's Enliven Therapeutics position peaked at $570K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.